1-(4-(1-(3,5,5,8,8-五甲基-5,6,7,8-四氢萘-2-基)乙烯基)苯基)乙酮 | 1349659-53-5

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 中文名称: 1-(4-(1-(3,5,5,8,8-五甲基-5,6,7,8-四氢萘-2-基)乙烯基)苯基)乙酮
• 英文名称: 1-(4-(1-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydronaphthalen-2-yl)vinyl)phenyl)ethanone
• 英文别名: 1-[4-[1-(3,5,5,8,8-pentamethyl-6,7-dihydronaphthalen-2-yl)ethenyl]phenyl]ethanone
• CAS: 1349659-53-5
• 化学式: C₂₅H₃₀O
• 分子量: 346.513
• InChiKey: SJDZRZNTLQWQAH-UHFFFAOYSA-N

物化性质

• 沸点：
  472.8±44.0 °C(Predicted)
• 密度：
  0.980±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  7.8
• 重原子数：
  26
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  甲基三苯基溴化膦 、 4-[(5,6,7,8-四氢-3,5,5,8,8-五甲基-2-萘基)羰基]苯甲酸甲酯 在 双(三甲基硅烷基)氨基钾 作用下， 以 甲苯 为溶剂， 反应 2.75h， 生成 1-(4-(1-(3,5,5,8,8-五甲基-5,6,7,8-四氢萘-2-基)乙烯基)苯基)乙酮 、 贝沙罗汀杂质10 、 (3,5,5,8,8-Pentamethyl-6,7-dihydronaphthalen-2-yl)-[4-[1-(3,5,5,8,8-pentamethyl-6,7-dihydronaphthalen-2-yl)ethenyl]phenyl]methanone 、 1,1,4,4,6-Pentamethyl-7-[1-[4-[1-(3,5,5,8,8-pentamethyl-6,7-dihydronaphthalen-2-yl)ethenyl]phenyl]ethenyl]-2,3-dihydronaphthalene 、 蓓萨罗丁中间体6
  参考文献：
  名称：

  [EN] PROCESS FOR THE PREPARATION OF HIGHLY PURE BEXAROTENE
  [FR] PROCÉDÉ DE PRÉPARATION DE BEXAROTÈNE HAUTEMENT PURIFIÉ

  摘要：

  本发明提供了一种改进的方法，用于制备化学式（I）的高纯度贝沙罗汀。本发明还提供了贝沙罗汀的杂质、这些杂质的分离和鉴定方法，以及将这些杂质用作参考标记和参考标准的用途。

  公开号：

  WO2011141928A1

文献信息

• Methods for inhibiting cell growth
  申请人：Zhao Yi

  公开号：US20090203720A1

  公开（公告）日：2009-08-13

  Cell growth is inhibited and/or cell death is induced in a cell by administering an RXR agonist and an inhibitor of casein kinase 1α. A cell or a tissue can be screened for enhanced susceptibility to cell death or interference with cell growth. Conditions characterized by uncontrolled cell growth or proliferation, such as a cancer, can be treated with inhibitors of casein kinase 1α.
• RETINOID-CONTAINING SUSTAINED RELEASE INTRAOCULAR IMPLANTS AND RELATED MATTERS
  申请人：Hughes Patrick M.

  公开号：US20110076318A1

  公开（公告）日：2011-03-31

  Biocompatible intraocular implants include a retinoid component and a biodegradable polymer that is effective to facilitate release of the retinoid component into an eye for an extended period of time. The therapeutic agents of the implants may be associated with a biodegradable polymer matrix, such as a matrix that is substantially free of a polyvinyl alcohol. The implants may be placed in an eye to treat or reduce the occurrence of one or more ocular conditions, such as retinal damage, including glaucoma and proliferative vitreoretinopathy.